董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Jonas Grossman Director 47 未披露 未持股 2021-09-30
William McKeever Chief Financial Officer and Director 66 未披露 未持股 2021-09-30
Sandip I. Patel Director 54 未披露 未持股 2021-09-30
James R. Neal Director 65 未披露 未持股 2021-09-30
Frances K. Heller Director 54 未披露 未持股 2021-09-30

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Sanjeev Satyal Chief Executive Officer 52 未披露 未持股 2021-09-30
William McKeever Chief Financial Officer and Director 66 未披露 未持股 2021-09-30

董事简历

中英对照 |  中文 |  英文
Jonas Grossman

Jonas Grossman,自2018年12月以来,我们的董事会成员是Chardan Capital Markets,LLC的总裁,他负责监督公司的全球资本市场计划,包括梦百合投资银行业务以及Chardan Affiliates对5SPACS的赞助,所有这些都完成了业务合并。Jonas自2018年3月起担任SPAC Chardan Healthcare AcquisitionCorp.的首席执行官兼总裁,直至2019年10月该公司与Biomx,Ltd.合并。NYSE:PHGE。Jonas现任Biomx董事。Jonas自2015年9月起担任Chardan总裁,自2003年12月起担任Chardan合伙人和资本市场主管。加入Chardan之前,Jonas从2001年到2003年担任Ramius Capital Group(一家全球多策略对冲基金)Vice President和首席交易员。Grossman自2006年12月起担任Cornix Advisors,LLC(一家位于纽约的对冲基金)创始合伙人。Grossman从2008年1月到2010年11月担任China Broadband(NASDAQ:SSC)董事。Jonas在Cornell University获得经济学学士学位,在NYU Stern School of Business获得工商管理硕士学位。


Jonas Grossman, has been our director since July 2019. Mr. Grossman was the Chief Executive Officer and President of Chardan Healthcare Acquisition Corp. from March 2018 until its merger in October 2019 with BiomX NYSE: PHGE. Mr. Grossman is currently a director of BiomX. Mr. Grossman was a director of LifeSci Acquisition Corp. from March 2020 until its merger in December 2020 with Vincera Pharma, Inc. (now Vincerx Pharma, Inc.) (NASDAQ: VINC). He currently serves as Chief Executive Officer, President and director of Chardan Healthcare Acquisition 2 Corp., which announced its merger with Renovacor in March 2021. Mr. Grossman currently serves as Chief Executive Officer, President and director of each of Chardan NexTech Acquisition Corp. and Chardan NexTech Acquisition 2 Corp. Mr. Grossman has served as Partner and Head of Capital Markets for Chardan Capital Markets, LLC, a New York headquartered broker/dealer, since December 2003 and has served as President of Chardan Capital Markets, LLC since September 2015. Since 2003 Mr. Grossman has overseen the firm's investment banking and capital markets activities and initiatives. He has extensive transactional experience, having led or managed more than 400 transactions during his tenure at Chardan. Since December 2006 Mr. Grossman has served as a founding partner for Cornix Advisors, LLC, a New York based hedge fund. From 2001 until 2003 Mr. Grossman worked at Ramius Capital Group, LLC, a global multi-strategy hedge fund where he served as Vice President and Head Trader. Mr. Grossman served as a director for Ideanomics, Inc. (formerly China Broadband, Inc.) (NASDAQ: IDEX) from January 2008 until November 2010. He holds a B.A. in Economics from Cornell University and an M.B.A. from NYU's Stern School of Business.
Jonas Grossman,自2018年12月以来,我们的董事会成员是Chardan Capital Markets,LLC的总裁,他负责监督公司的全球资本市场计划,包括梦百合投资银行业务以及Chardan Affiliates对5SPACS的赞助,所有这些都完成了业务合并。Jonas自2018年3月起担任SPAC Chardan Healthcare AcquisitionCorp.的首席执行官兼总裁,直至2019年10月该公司与Biomx,Ltd.合并。NYSE:PHGE。Jonas现任Biomx董事。Jonas自2015年9月起担任Chardan总裁,自2003年12月起担任Chardan合伙人和资本市场主管。加入Chardan之前,Jonas从2001年到2003年担任Ramius Capital Group(一家全球多策略对冲基金)Vice President和首席交易员。Grossman自2006年12月起担任Cornix Advisors,LLC(一家位于纽约的对冲基金)创始合伙人。Grossman从2008年1月到2010年11月担任China Broadband(NASDAQ:SSC)董事。Jonas在Cornell University获得经济学学士学位,在NYU Stern School of Business获得工商管理硕士学位。
Jonas Grossman, has been our director since July 2019. Mr. Grossman was the Chief Executive Officer and President of Chardan Healthcare Acquisition Corp. from March 2018 until its merger in October 2019 with BiomX NYSE: PHGE. Mr. Grossman is currently a director of BiomX. Mr. Grossman was a director of LifeSci Acquisition Corp. from March 2020 until its merger in December 2020 with Vincera Pharma, Inc. (now Vincerx Pharma, Inc.) (NASDAQ: VINC). He currently serves as Chief Executive Officer, President and director of Chardan Healthcare Acquisition 2 Corp., which announced its merger with Renovacor in March 2021. Mr. Grossman currently serves as Chief Executive Officer, President and director of each of Chardan NexTech Acquisition Corp. and Chardan NexTech Acquisition 2 Corp. Mr. Grossman has served as Partner and Head of Capital Markets for Chardan Capital Markets, LLC, a New York headquartered broker/dealer, since December 2003 and has served as President of Chardan Capital Markets, LLC since September 2015. Since 2003 Mr. Grossman has overseen the firm's investment banking and capital markets activities and initiatives. He has extensive transactional experience, having led or managed more than 400 transactions during his tenure at Chardan. Since December 2006 Mr. Grossman has served as a founding partner for Cornix Advisors, LLC, a New York based hedge fund. From 2001 until 2003 Mr. Grossman worked at Ramius Capital Group, LLC, a global multi-strategy hedge fund where he served as Vice President and Head Trader. Mr. Grossman served as a director for Ideanomics, Inc. (formerly China Broadband, Inc.) (NASDAQ: IDEX) from January 2008 until November 2010. He holds a B.A. in Economics from Cornell University and an M.B.A. from NYU's Stern School of Business.
William McKeever

William McKeever自2021年5月起担任公司首席财务官。McKeever先生在医疗保健行业拥有超过20年的经验,包括股票研究、投资组合管理和投资银行的各种角色。自2017年以来,McKeever先生一直担任多家公司的顾问,这些公司正在开发突破性技术来治疗医疗保健行业的疾病。从2010年到2016年,他曾担任First Bridgehouse Securities(精品投资公司)的董事总经理,在那里他曾担任医疗保健行业广泛领域的早期公司的顾问。在此之前,McKeever先生是一名卖方股票分析师,负责管理护理行业,包括1997年至2000年的PaineWebber和2000年至2005年的UBS。在PaineWebber和瑞银任职期间,他曾担任董事总经理,并根据《机构投资者》杂志对全美分析师的调查,连续几年被该杂志评为全美分析师。在瑞银工作期间,他参与了几家管理式医疗公司的首次公开发行。从2005年到2009年,McKeever先生担任董事总经理,管理美林公司的主要信贷集团PCG的所有医疗保健投资,包括制药,医疗设备,服务和生物技术。PCG是一家内部基金,管理全球所有行业的债务和股权投资。McKeever先生在丹尼森大学获得经济学学士学位,并在宾夕法尼亚大学沃顿商学院获得金融硕士学位。


William McKeever has served as our Chief Financial Officer since May 2021. Mr. McKeever has more than 20 years of experience in the healthcare industry encompassing various roles in equity research, portfolio management and investment banking. Since 2017 Mr. McKeever has worked as a consultant to various companies that are creating breakthrough technologies to treat diseases in the healthcare industry. From 2010 to 2016 Mr. McKeever was Managing Director of First Bridgehouse Securities, a boutique investment firm, where he was a consultant to early-stage companies across a broad range of sectors within the healthcare industry. Prior to that, Mr. McKeever was a sell-side equity analyst covering the managed care industry at firms including PaineWebber from 1997 to 2000 and UBS from 2000 to 2005. While at PaineWebber and UBS, he was a managing director and was ranked for several year as an All-American Analyst by Institutional Investor magazine based on its poll of analysts around the country. While at UBS, he was involved in several initial public offerings of managed care companies. From 2005 to 2009 From 2005 to 2009 Mr. McKeever was a Managing Director managing all health care investments including pharmaceuticals, medical devices, services and biotechnology in the Principal Credit Group PCG of Merrill Lynch. PCG was an internal fund that managed debt and equity investments in all sectors globally. Mr. McKeever earned his B.A. in Economics from Denison University and his M.B.A. in Finance from the Wharton School of the University of Pennsylvania.
William McKeever自2021年5月起担任公司首席财务官。McKeever先生在医疗保健行业拥有超过20年的经验,包括股票研究、投资组合管理和投资银行的各种角色。自2017年以来,McKeever先生一直担任多家公司的顾问,这些公司正在开发突破性技术来治疗医疗保健行业的疾病。从2010年到2016年,他曾担任First Bridgehouse Securities(精品投资公司)的董事总经理,在那里他曾担任医疗保健行业广泛领域的早期公司的顾问。在此之前,McKeever先生是一名卖方股票分析师,负责管理护理行业,包括1997年至2000年的PaineWebber和2000年至2005年的UBS。在PaineWebber和瑞银任职期间,他曾担任董事总经理,并根据《机构投资者》杂志对全美分析师的调查,连续几年被该杂志评为全美分析师。在瑞银工作期间,他参与了几家管理式医疗公司的首次公开发行。从2005年到2009年,McKeever先生担任董事总经理,管理美林公司的主要信贷集团PCG的所有医疗保健投资,包括制药,医疗设备,服务和生物技术。PCG是一家内部基金,管理全球所有行业的债务和股权投资。McKeever先生在丹尼森大学获得经济学学士学位,并在宾夕法尼亚大学沃顿商学院获得金融硕士学位。
William McKeever has served as our Chief Financial Officer since May 2021. Mr. McKeever has more than 20 years of experience in the healthcare industry encompassing various roles in equity research, portfolio management and investment banking. Since 2017 Mr. McKeever has worked as a consultant to various companies that are creating breakthrough technologies to treat diseases in the healthcare industry. From 2010 to 2016 Mr. McKeever was Managing Director of First Bridgehouse Securities, a boutique investment firm, where he was a consultant to early-stage companies across a broad range of sectors within the healthcare industry. Prior to that, Mr. McKeever was a sell-side equity analyst covering the managed care industry at firms including PaineWebber from 1997 to 2000 and UBS from 2000 to 2005. While at PaineWebber and UBS, he was a managing director and was ranked for several year as an All-American Analyst by Institutional Investor magazine based on its poll of analysts around the country. While at UBS, he was involved in several initial public offerings of managed care companies. From 2005 to 2009 From 2005 to 2009 Mr. McKeever was a Managing Director managing all health care investments including pharmaceuticals, medical devices, services and biotechnology in the Principal Credit Group PCG of Merrill Lynch. PCG was an internal fund that managed debt and equity investments in all sectors globally. Mr. McKeever earned his B.A. in Economics from Denison University and his M.B.A. in Finance from the Wharton School of the University of Pennsylvania.
Sandip I. Patel

Sandip I.Patel自2021年4月起担任我们的董事会成员。Patel先生一直是Sandip I.Patel,P.A.的律师和公司业务顾问,这是一家由Patel先生于2000年创立的律师事务所。自2017年以来,Patel先生还担任医疗设备公司Channel Investments,LLC的首席法律顾问。Patel先生一直参与与医疗保健、保险和金融服务领域的公司相关的形成、收购、发展、增长和流动性事件。Patel先生目前在广泛的行业中拥有公共和私人投资,专注于医疗设备,生物技术,医疗保健服务和相关技术,以及金融科技和相关服务。Patel先生也是Atlasbanc的联合创始股东,也是Anderen Bank的联合创始股东和董事会成员。他曾任职Avatar Property and Casualty Insurance Company(佛罗里达州的业主保险公司)的董事会。Patel先生是The Orion Group of Companies(一家全方位服务的房地产开发公司)的创始人,总裁兼首席执行官。此前,Patel先生担任国家健康保险公司新业务开发和并购团队的负责人。Patel先生代表WellCare监督所有的法律、监管和政府事务,同时担任该公司的总法律顾问和合伙人。自2021年2月以来,Patel先生一直担任Quantum FinTech Acquisition Corporation(一家特殊目的收购公司)的董事。Patel先生拥有斯泰森大学法学院的法学博士学位和乔治亚大学的金融学士学位。


Sandip I. Patel has served as a member of board since February 2024. Previoly, he served as a member of the Quantum Board from October 2020 to February 2024. Mr. Patel has been an attorney and corporate biness consultant at Sandip I. Patel, P.A., a law firm founded by Mr. Patel in 2000. Since 2017, Mr. Patel has also served as Chief Legal Counsel of Channel Investments, LLC, a medical device company. Mr. Patel has been involved in the formation, acquisition, development, growth, and liquidity events related to companies in the healthcare, insurance and financial services fields. Mr. Patel currently holds public and private investments in a wide range of indtries with a foc on medical devices, biotechnology, healthcare services and related technologies, as ll as FinTech and related services. Mr. Patel is also a co founding stockholder of AtlasBanc Holdings, and was a co founding stockholder and board member of Anderen Bank. Mr. Patel was the Founder, President and Chief Executive Officer of the Orion group of companies, a full service real estate development company. Previoly, Mr. Patel served as Head of the New Biness Development and M&A team to national health insurance companies. Mr. Patel oversaw all legal, regulatory and governmental affairs on behalf of llCare, while serving as the General Counsel and a partner in the company. Since September 2021, Mr. Patel previoly served as a director of Monterey Bio Acquisition Corporation, a former special purpose acquisition company (Nasdaq: MTRY). Mr. Patel received his JD degree from the Stetson University College of Law, and a B.B.A in Finance from the University of Georgia.
Sandip I.Patel自2021年4月起担任我们的董事会成员。Patel先生一直是Sandip I.Patel,P.A.的律师和公司业务顾问,这是一家由Patel先生于2000年创立的律师事务所。自2017年以来,Patel先生还担任医疗设备公司Channel Investments,LLC的首席法律顾问。Patel先生一直参与与医疗保健、保险和金融服务领域的公司相关的形成、收购、发展、增长和流动性事件。Patel先生目前在广泛的行业中拥有公共和私人投资,专注于医疗设备,生物技术,医疗保健服务和相关技术,以及金融科技和相关服务。Patel先生也是Atlasbanc的联合创始股东,也是Anderen Bank的联合创始股东和董事会成员。他曾任职Avatar Property and Casualty Insurance Company(佛罗里达州的业主保险公司)的董事会。Patel先生是The Orion Group of Companies(一家全方位服务的房地产开发公司)的创始人,总裁兼首席执行官。此前,Patel先生担任国家健康保险公司新业务开发和并购团队的负责人。Patel先生代表WellCare监督所有的法律、监管和政府事务,同时担任该公司的总法律顾问和合伙人。自2021年2月以来,Patel先生一直担任Quantum FinTech Acquisition Corporation(一家特殊目的收购公司)的董事。Patel先生拥有斯泰森大学法学院的法学博士学位和乔治亚大学的金融学士学位。
Sandip I. Patel has served as a member of board since February 2024. Previoly, he served as a member of the Quantum Board from October 2020 to February 2024. Mr. Patel has been an attorney and corporate biness consultant at Sandip I. Patel, P.A., a law firm founded by Mr. Patel in 2000. Since 2017, Mr. Patel has also served as Chief Legal Counsel of Channel Investments, LLC, a medical device company. Mr. Patel has been involved in the formation, acquisition, development, growth, and liquidity events related to companies in the healthcare, insurance and financial services fields. Mr. Patel currently holds public and private investments in a wide range of indtries with a foc on medical devices, biotechnology, healthcare services and related technologies, as ll as FinTech and related services. Mr. Patel is also a co founding stockholder of AtlasBanc Holdings, and was a co founding stockholder and board member of Anderen Bank. Mr. Patel was the Founder, President and Chief Executive Officer of the Orion group of companies, a full service real estate development company. Previoly, Mr. Patel served as Head of the New Biness Development and M&A team to national health insurance companies. Mr. Patel oversaw all legal, regulatory and governmental affairs on behalf of llCare, while serving as the General Counsel and a partner in the company. Since September 2021, Mr. Patel previoly served as a director of Monterey Bio Acquisition Corporation, a former special purpose acquisition company (Nasdaq: MTRY). Mr. Patel received his JD degree from the Stetson University College of Law, and a B.B.A in Finance from the University of Georgia.
James R. Neal

James R.Neal已同意在注册声明生效之日立即担任我们的董事会主席,该声明构成了本招股说明书的一部分。自2016年以来,Neal先生一直担任XOMA Corporation NASDAQ:标记临床研究的首席执行官兼董事,这是一家生物技术特许权使用费聚合器,此前曾担任其高级副总裁兼首席运营官。他于2009年加入标记临床研究,担任其业务开发副总裁。在加入标记临床研究之前,Neal先生是Entelos,Inc.的代理首席执行官,该公司是一家领先的生物模拟公司。此前,Entelos在2007年收购了Iconix Biosciences,这是一家私人控股公司,Neal先生在该公司担任首席执行官,并与Bristol-Myers Squibb,Abbott Labs,Eli Lilly和美国食品和药物管理局建立了多年的合作关系。从1999年到2002年,他担任Incyte Genomics的执行副总裁,领导制药公司合作者和合作伙伴的全球商业活动,包括Pfizer,Aventis和Schering-Plough,以及公司的销售、营销和业务发展活动。此前,他曾担任孟山都公司的高管,并担任多种职务。Neal先生还担任临床阶段生物制药公司Palisade Bio的董事会主席。尼尔先生获得了理学学士学位。在农业和他的硕士学位。分别来自加拿大马尼托巴大学的遗传学和植物育种专业,并拥有密苏里州圣路易斯华盛顿大学的行政管理M.B.A.学位。


James R. Neal has served as a member of the Company's Board since April 2021. Previously, Mr. Neal served as a member of the LBS Board since November 2017. Mr. Neal has also served as the Chief Executive Officer and board member of XOMA Corporation, a biotechnology company, since December 2016. Previously, Mr. Neal served as the Chief Business Officer of Entelos Inc. from September 2007 to July 2010. From July 2002 to August 2007 Mr. Neal served as the Chief Executive Officer of Iconix Biosciences, Inc. From 1999 to 2002 Mr. Neal served as the Chief Executive Officer of Incyte Genomics. Mr. Neal received a B.S. in biology and an M.S. in genetics and plant breeding from the University of Manitoba, Canada, and an executive MBA from Washington University in St. Louis, Missouri.
James R.Neal已同意在注册声明生效之日立即担任我们的董事会主席,该声明构成了本招股说明书的一部分。自2016年以来,Neal先生一直担任XOMA Corporation NASDAQ:标记临床研究的首席执行官兼董事,这是一家生物技术特许权使用费聚合器,此前曾担任其高级副总裁兼首席运营官。他于2009年加入标记临床研究,担任其业务开发副总裁。在加入标记临床研究之前,Neal先生是Entelos,Inc.的代理首席执行官,该公司是一家领先的生物模拟公司。此前,Entelos在2007年收购了Iconix Biosciences,这是一家私人控股公司,Neal先生在该公司担任首席执行官,并与Bristol-Myers Squibb,Abbott Labs,Eli Lilly和美国食品和药物管理局建立了多年的合作关系。从1999年到2002年,他担任Incyte Genomics的执行副总裁,领导制药公司合作者和合作伙伴的全球商业活动,包括Pfizer,Aventis和Schering-Plough,以及公司的销售、营销和业务发展活动。此前,他曾担任孟山都公司的高管,并担任多种职务。Neal先生还担任临床阶段生物制药公司Palisade Bio的董事会主席。尼尔先生获得了理学学士学位。在农业和他的硕士学位。分别来自加拿大马尼托巴大学的遗传学和植物育种专业,并拥有密苏里州圣路易斯华盛顿大学的行政管理M.B.A.学位。
James R. Neal has served as a member of the Company's Board since April 2021. Previously, Mr. Neal served as a member of the LBS Board since November 2017. Mr. Neal has also served as the Chief Executive Officer and board member of XOMA Corporation, a biotechnology company, since December 2016. Previously, Mr. Neal served as the Chief Business Officer of Entelos Inc. from September 2007 to July 2010. From July 2002 to August 2007 Mr. Neal served as the Chief Executive Officer of Iconix Biosciences, Inc. From 1999 to 2002 Mr. Neal served as the Chief Executive Officer of Incyte Genomics. Mr. Neal received a B.S. in biology and an M.S. in genetics and plant breeding from the University of Manitoba, Canada, and an executive MBA from Washington University in St. Louis, Missouri.
Frances K. Heller

Frances K. Heller,2008年8月起,她担任商业发展执行副总裁。2003年12月至加入Exelixis, 她担任Novartis AG。的全球研究组织诺华生物医学研究所(Novartis Institutes for Biomedical Research (NIBR))的战略联盟主管。在该职位上,她协商交易,许诺初期资产加快NIBR的药物发现与开发工作。就职于NIBR之前, 2001至2003年,她担任Signature BioScience, Inc.的公司发展与法律事务副总裁,Signature BioScience, Inc.是肿瘤药物研发公司,她监督所有商业发展和法律事项。就职于Signature Bioscience之前,1998至2001ian,她在Celera Genomics担任职位,责任越来越重要,最近担任公司与知识产权顾问和法律部门主管,负责企业与商业交易和基因发现协作。2011年1月起,她担任私人生物技术公司Admimab, LLC的董事会成员。她是加利福尼亚州律师协会(California State Bar)的成员,有美国专利与商标局(United States Patent and Trademark Office)颁发的许可。她在金州州立大学法学院(Golden Gate University School of Law)获得法学博士学位,在美国大学(American University)获得生物硕士学位,在杜兰大学(Tulane University)获得生物学士学位。


Frances K. Heller has agreed to serve on our board of directors immediately upon the effective date of the registration statement of which this prospectus forms a part. For more than 25 years, Ms. Heller has been an executive and director in the pharmaceutical and biotech industries with expertise in business development, strategic transactions, and legal affairs. In this sector, Ms. Heller was most recently Senior Vice President of Business Development at Bristol-Myers Squibb and a Trustee of the Bristol-Myers Squibb Foundation, from 2012 to 2014. In 2015 Ms. Heller founded Good2Go, Inc., an IoT technology company, for which she currently serves as Chair and Chief Executive Officer. Ms. Heller is a member of the board of directors of Affinivax, a private early-stage vaccine company, the Co-Chair of Lava Maex, a non-profit clean water/mobile hygiene organization and is also on the board of advisers at Tulane University. She previously served as a board member of Zafgen, Inc. Nasdaq: ZFGN (currently Larimar Therapeutics, Inc.) from 2014 to 2017. She also previously served as Trustee of the Dana Farber Cancer Institute. Ms. Heller is a member of the California State Bar and is licensed by the U.S. Patent and Trademark Office. Ms. Heller holds a B.S. in Biology from Tulane University, an M.A. in Biology from American University and a J.D. degree from Golden Gate University.
Frances K. Heller,2008年8月起,她担任商业发展执行副总裁。2003年12月至加入Exelixis, 她担任Novartis AG。的全球研究组织诺华生物医学研究所(Novartis Institutes for Biomedical Research (NIBR))的战略联盟主管。在该职位上,她协商交易,许诺初期资产加快NIBR的药物发现与开发工作。就职于NIBR之前, 2001至2003年,她担任Signature BioScience, Inc.的公司发展与法律事务副总裁,Signature BioScience, Inc.是肿瘤药物研发公司,她监督所有商业发展和法律事项。就职于Signature Bioscience之前,1998至2001ian,她在Celera Genomics担任职位,责任越来越重要,最近担任公司与知识产权顾问和法律部门主管,负责企业与商业交易和基因发现协作。2011年1月起,她担任私人生物技术公司Admimab, LLC的董事会成员。她是加利福尼亚州律师协会(California State Bar)的成员,有美国专利与商标局(United States Patent and Trademark Office)颁发的许可。她在金州州立大学法学院(Golden Gate University School of Law)获得法学博士学位,在美国大学(American University)获得生物硕士学位,在杜兰大学(Tulane University)获得生物学士学位。
Frances K. Heller has agreed to serve on our board of directors immediately upon the effective date of the registration statement of which this prospectus forms a part. For more than 25 years, Ms. Heller has been an executive and director in the pharmaceutical and biotech industries with expertise in business development, strategic transactions, and legal affairs. In this sector, Ms. Heller was most recently Senior Vice President of Business Development at Bristol-Myers Squibb and a Trustee of the Bristol-Myers Squibb Foundation, from 2012 to 2014. In 2015 Ms. Heller founded Good2Go, Inc., an IoT technology company, for which she currently serves as Chair and Chief Executive Officer. Ms. Heller is a member of the board of directors of Affinivax, a private early-stage vaccine company, the Co-Chair of Lava Maex, a non-profit clean water/mobile hygiene organization and is also on the board of advisers at Tulane University. She previously served as a board member of Zafgen, Inc. Nasdaq: ZFGN (currently Larimar Therapeutics, Inc.) from 2014 to 2017. She also previously served as Trustee of the Dana Farber Cancer Institute. Ms. Heller is a member of the California State Bar and is licensed by the U.S. Patent and Trademark Office. Ms. Heller holds a B.S. in Biology from Tulane University, an M.A. in Biology from American University and a J.D. degree from Golden Gate University.

高管简历

中英对照 |  中文 |  英文
Sanjeev Satyal

Sanjeev Satyal自2021年4月起担任我们的首席执行官。从2018年到2021年2月,Satyal博士担任PH Pharma Co.的首席执行官。该公司是一家临床阶段的生物制药公司,专注于开发创新的医疗保健产品,以满足未满足的临床和患者需求。从2015年到2021年2月,他还担任PH Pharma的研发副总裁。此前,Satyal博士曾担任StemGuard Therapeutics(一家生物技术公司,专注于开发退行性疾病的疗法)的生物学副总裁。此前,他曾担任Stempar Sciences公司的研究董事,以及OncoMed Pharmaceuticals公司的癌症生物学董事。萨蒂亚尔博士是基因泰克公司的博士后。Satyal博士是30多项美国已发布或正在申请的专利的发明者,以及他们在各个制药领域的外国同行,还与人合著了几本科学出版物。萨蒂亚尔博士获得了理学学士学位。在孟买大学圣泽维尔学院获得生命科学硕士学位。普纳大学生物技术专业,西北大学生物化学博士。


Sanjeev Satyal has served as our Chief Executive Officer since April 2021. From 2018 to February 2021 Dr. Satyal served as Chief Executive Officer of pH Pharma Co. Inc., a clinical-stage biopharmaceutical company focused on developing innovative healthcare products for unmet clinical and patient needs. From 2015 to February 2021 he has also served as Vice President of Research & Development at pH Pharma. Previously, Dr. Satyal served as Vice President, Biology at StemGuard Therapeutics, a biotech company focused on developing therapies for degenerative diseases. Prior to that he worked as a Director of Research at StemPar Sciences and as a Director of Cancer Biology at OncoMed Pharmaceuticals. Dr. Satyal was a postdoctoral fellow at Genentech. Dr. Satyal is the inventor of over 30 U.S. issued or pending patents, and their foreign counterparts, in various pharmaceutical areas and has also co-authored several scientific publications. Dr. Satyal earned a B.Sc. in Life Sciences at St. Xavier’s College, University of Bombay, an M.Sc. in Biotechnology at the University of Poona and a Ph.D. in Biochemistry at Northwestern University.
Sanjeev Satyal自2021年4月起担任我们的首席执行官。从2018年到2021年2月,Satyal博士担任PH Pharma Co.的首席执行官。该公司是一家临床阶段的生物制药公司,专注于开发创新的医疗保健产品,以满足未满足的临床和患者需求。从2015年到2021年2月,他还担任PH Pharma的研发副总裁。此前,Satyal博士曾担任StemGuard Therapeutics(一家生物技术公司,专注于开发退行性疾病的疗法)的生物学副总裁。此前,他曾担任Stempar Sciences公司的研究董事,以及OncoMed Pharmaceuticals公司的癌症生物学董事。萨蒂亚尔博士是基因泰克公司的博士后。Satyal博士是30多项美国已发布或正在申请的专利的发明者,以及他们在各个制药领域的外国同行,还与人合著了几本科学出版物。萨蒂亚尔博士获得了理学学士学位。在孟买大学圣泽维尔学院获得生命科学硕士学位。普纳大学生物技术专业,西北大学生物化学博士。
Sanjeev Satyal has served as our Chief Executive Officer since April 2021. From 2018 to February 2021 Dr. Satyal served as Chief Executive Officer of pH Pharma Co. Inc., a clinical-stage biopharmaceutical company focused on developing innovative healthcare products for unmet clinical and patient needs. From 2015 to February 2021 he has also served as Vice President of Research & Development at pH Pharma. Previously, Dr. Satyal served as Vice President, Biology at StemGuard Therapeutics, a biotech company focused on developing therapies for degenerative diseases. Prior to that he worked as a Director of Research at StemPar Sciences and as a Director of Cancer Biology at OncoMed Pharmaceuticals. Dr. Satyal was a postdoctoral fellow at Genentech. Dr. Satyal is the inventor of over 30 U.S. issued or pending patents, and their foreign counterparts, in various pharmaceutical areas and has also co-authored several scientific publications. Dr. Satyal earned a B.Sc. in Life Sciences at St. Xavier’s College, University of Bombay, an M.Sc. in Biotechnology at the University of Poona and a Ph.D. in Biochemistry at Northwestern University.
William McKeever

William McKeever自2021年5月起担任公司首席财务官。McKeever先生在医疗保健行业拥有超过20年的经验,包括股票研究、投资组合管理和投资银行的各种角色。自2017年以来,McKeever先生一直担任多家公司的顾问,这些公司正在开发突破性技术来治疗医疗保健行业的疾病。从2010年到2016年,他曾担任First Bridgehouse Securities(精品投资公司)的董事总经理,在那里他曾担任医疗保健行业广泛领域的早期公司的顾问。在此之前,McKeever先生是一名卖方股票分析师,负责管理护理行业,包括1997年至2000年的PaineWebber和2000年至2005年的UBS。在PaineWebber和瑞银任职期间,他曾担任董事总经理,并根据《机构投资者》杂志对全美分析师的调查,连续几年被该杂志评为全美分析师。在瑞银工作期间,他参与了几家管理式医疗公司的首次公开发行。从2005年到2009年,McKeever先生担任董事总经理,管理美林公司的主要信贷集团PCG的所有医疗保健投资,包括制药,医疗设备,服务和生物技术。PCG是一家内部基金,管理全球所有行业的债务和股权投资。McKeever先生在丹尼森大学获得经济学学士学位,并在宾夕法尼亚大学沃顿商学院获得金融硕士学位。


William McKeever has served as our Chief Financial Officer since May 2021. Mr. McKeever has more than 20 years of experience in the healthcare industry encompassing various roles in equity research, portfolio management and investment banking. Since 2017 Mr. McKeever has worked as a consultant to various companies that are creating breakthrough technologies to treat diseases in the healthcare industry. From 2010 to 2016 Mr. McKeever was Managing Director of First Bridgehouse Securities, a boutique investment firm, where he was a consultant to early-stage companies across a broad range of sectors within the healthcare industry. Prior to that, Mr. McKeever was a sell-side equity analyst covering the managed care industry at firms including PaineWebber from 1997 to 2000 and UBS from 2000 to 2005. While at PaineWebber and UBS, he was a managing director and was ranked for several year as an All-American Analyst by Institutional Investor magazine based on its poll of analysts around the country. While at UBS, he was involved in several initial public offerings of managed care companies. From 2005 to 2009 From 2005 to 2009 Mr. McKeever was a Managing Director managing all health care investments including pharmaceuticals, medical devices, services and biotechnology in the Principal Credit Group PCG of Merrill Lynch. PCG was an internal fund that managed debt and equity investments in all sectors globally. Mr. McKeever earned his B.A. in Economics from Denison University and his M.B.A. in Finance from the Wharton School of the University of Pennsylvania.
William McKeever自2021年5月起担任公司首席财务官。McKeever先生在医疗保健行业拥有超过20年的经验,包括股票研究、投资组合管理和投资银行的各种角色。自2017年以来,McKeever先生一直担任多家公司的顾问,这些公司正在开发突破性技术来治疗医疗保健行业的疾病。从2010年到2016年,他曾担任First Bridgehouse Securities(精品投资公司)的董事总经理,在那里他曾担任医疗保健行业广泛领域的早期公司的顾问。在此之前,McKeever先生是一名卖方股票分析师,负责管理护理行业,包括1997年至2000年的PaineWebber和2000年至2005年的UBS。在PaineWebber和瑞银任职期间,他曾担任董事总经理,并根据《机构投资者》杂志对全美分析师的调查,连续几年被该杂志评为全美分析师。在瑞银工作期间,他参与了几家管理式医疗公司的首次公开发行。从2005年到2009年,McKeever先生担任董事总经理,管理美林公司的主要信贷集团PCG的所有医疗保健投资,包括制药,医疗设备,服务和生物技术。PCG是一家内部基金,管理全球所有行业的债务和股权投资。McKeever先生在丹尼森大学获得经济学学士学位,并在宾夕法尼亚大学沃顿商学院获得金融硕士学位。
William McKeever has served as our Chief Financial Officer since May 2021. Mr. McKeever has more than 20 years of experience in the healthcare industry encompassing various roles in equity research, portfolio management and investment banking. Since 2017 Mr. McKeever has worked as a consultant to various companies that are creating breakthrough technologies to treat diseases in the healthcare industry. From 2010 to 2016 Mr. McKeever was Managing Director of First Bridgehouse Securities, a boutique investment firm, where he was a consultant to early-stage companies across a broad range of sectors within the healthcare industry. Prior to that, Mr. McKeever was a sell-side equity analyst covering the managed care industry at firms including PaineWebber from 1997 to 2000 and UBS from 2000 to 2005. While at PaineWebber and UBS, he was a managing director and was ranked for several year as an All-American Analyst by Institutional Investor magazine based on its poll of analysts around the country. While at UBS, he was involved in several initial public offerings of managed care companies. From 2005 to 2009 From 2005 to 2009 Mr. McKeever was a Managing Director managing all health care investments including pharmaceuticals, medical devices, services and biotechnology in the Principal Credit Group PCG of Merrill Lynch. PCG was an internal fund that managed debt and equity investments in all sectors globally. Mr. McKeever earned his B.A. in Economics from Denison University and his M.B.A. in Finance from the Wharton School of the University of Pennsylvania.